Curcumin enhances the anticancer effects of trichostatin a in breast cancer cells

Molecular Carcinogenesis

Volumn 52, Issue 5, 2013, Pages 404-411

  Yan, Guang ^a   Graham, Kimmer ^a   Lanza Jacoby, Susan ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Breast cancer; Curcumin; Histone deacetylase inhibitors

Indexed keywords

CASPASE 3; CURCUMIN; CYCLIN D1; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PROTEIN KINASE B; PROTEIN P21; PROTEIN P27; PROTEIN P53; SYNAPTOPHYSIN; TRICHOSTATIN A;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CELL CYCLE G0 PHASE; CELL VIABILITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; BREAST NEOPLASMS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL SURVIVAL; CURCUMIN; CYCLIN D1; ENZYME INHIBITORS; FEMALE; HUMANS; HYDROXAMIC ACIDS; IMIDAZOLES; MAP KINASE KINASE 4; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PYRIDINES;

EID: 84876121166     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.21875     Document Type: Article

References (33)

1. Gusterson BA, Gelber RD, Goldhirsch A, et al. Prognostic importance of c-erbB2 expression in breast cancer. International Breast Cancer Study Group. J ClinOncol 1992; 10: 1049-1056.
2. Slamon DJ, Godopphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-712.
3. Kuo MH, Allis CD. Role of histone acetylases and histone acetylases in gene regulation. Bioessay 1998; 20: 615-626.
4. Cress WD, Seto E. Histone deacetylases, transcritptional control, and cancer. J Cell Physiol 2000; 184: 1-16.
5. Gray SG, Ekstrom TJ. The human histone deacetylase family. Exp Cell Res 2001; 262: 75-83.
6. Mishra SK, Mandal M, Mazumdar A, Kumar R. Dynamic chromatin remodeling on the HER2 promoter in human breast cancer cells. FEBS Lett 2001; 507: 88-94.
7. Citri A, Kochupurakkal BS, Yarden Y. The achilles heel of ErbB-2/HER2: Regulation by the Hsp90 chaperone machine and potential for pharmacological intervention. Cell Cycle. 2004; 3: 51-60.
8. Vigushin DM, Ali S, Pace PE, et al. Tricostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin Cancer Res 2001; 7: 971-976.
9. Bali P, Pranpat M, Swaby R, et al. Activity of Superoylanilidehydroxamic acid against human breast cancer cells with amplification of Her-2. Clin Cancer Res 2005; 11: 6382-6389.
10. Huang X, Gao L, Wang S, Lee C-K, Ordentlich P, Lin B. HDAC inhibitor SNDX-275 induces apoptosis in erbB2-overexpressing breast cancer cells via downregulation of erbB3 expression. Clin Cancer Res 2009; 69: 8403-8411.
11. Chen J, Bai H, Wang C, Kang J. Tricostatin A improves the anticancer activity of low concentrations of curcumin in human leukemia cells. Pharmazie 2006; 61: 710-716.
12. Chen J, Wang G, Wang L, Kang J, Wang J. Curcumin p38-independently enhances the anticancer activity of valproic acid in human leukemia cells. Eur J Pharm Sci 2010; 41: 210-210.
13. Giommarelli C, Zuco V, Favini E, et al. The enhancement of antiproliferative and proapoptotic activity of histone deacetylase inhibitors by curcumin is mediated by Hsp 90 inhibition. Cell Mol Life Sci 2010; 67: 995-1004.
14. Anand P, Sundaram C, Jhurani S, Kunnumakkara SB, Aggarwal BB. Curcumin and cancer: An "old-age" disease with an "age-old" solution. Cancer Lett 2008; 267: 133-164.
15. Lee SJ, Krauthauser C, Maduskuie Fawcett PT, Olson JM, Rajasekaran SA. Curcumin-induced HDAC inhibition and attenuation of medulloblastoma growth in vitro and in vivo. BMC Cancer 2011; 11: 144-157.
16. Kang SK, Cha SH, Jeon HG. Curcumin-induced histone hyperacetylation enhances caspase 3-dependent glioma cell death and neurogenesis of neuralprogenitor cells. Stem Cells Dev 2006; 15: 165-174.
17. Balasubramanyam K, Varier RA, Altaf M, et al. Curcumin, a novel p300/CREB binding protein-specific inhibitor of acetytransferase, represses the acetylation of histone/nonhistone proteins and histone acetylase-dependent chromatin transcription. J BiolChem 2004; 279: 51163-51171.
18. Eliseeva ED, Valkov V, Jung M, Jung MO. Characterization of novel inhibitors of histone acetyltransferases. Mol Cancer Ther 2007; 6: 2391-2398.
19. Vermeulin K, Van Bockstaele DR, Berneman ZN. The cell cycle: A review of regulation, deregulation and therapeutic regulation, deregulation, and therapeutic targets. Cell Prolif 2003; 36: 131-149.
20. Nagata Y, Todokoro K. Requirement of activation of JNK and p38 for environmental stress-induced erythroid differentiation and apoptosis and of inhibition of ERK for apoptosis. Blood 1999; 94: 8530863.
21. Mehta K, Pantazis P, McQueen T, Aggarwal BB. Antiproliferative effect of curcumin (diferuloymethane) against human breast cancer cells. Anticancer Drugs 1997; 8: 470-481.
22. Choudhuri T, Pal S, Das T, Sa G. Curcumin selectively induces apoptosis in deregulated cyclin D1-expressed cells at G2 phase of cell cycle in a p53-dependent manner. J Biol Chem 2005; 280: 20059-20068.
23. Hua W-F, Fu Y-S, Liao Y-J, et al. Curcumin induces down-regulation of EZH2 expression through the MAPK pathway in MDA-MB-435 human breast cancer cells. Eur J Pharmacol 2011; 637: 16-21.
24. Zhou C, Qui L, Sun Y, et al. Inhibition of EGFR/PI3K/Akt cell survival pathway promotes TSA's effect on cell death and migration in human ovarian cancer cells. Int J Oncol 2006; 29: 269-278.
25. Squires MS, Hudson EA, Howells L, et al. Relevance of mitogen activated protein kinase (MAPK) and phosphotidylinositol-3-kinase/protein kinase B (PI3K/PKB) pathways to induction of apoptosis by curcumin in breast cells. Biochem Pharmacol 2003; 65: 361-376.
26. Su S, Shen G, Khor TO, Kim J-H, Kong A-N. Curcumin inhibits Akt/mammalian target of rapamycin signaling through protein phosphatase-dependent mechanism. Mol Can Ther 2008; 7: 2609-2620.
27. Mukhopadhyay A, Banerjee S, Stafford LJ, Xia C, Liu M, Aggarwal B. Curcumin-induced suppression of cell proliferation correlates with down-regulation of cyclin D1 expression and CDK4-mediated retinoblastoma protein phosphorylation. Oncogene 2002; 21: 8852-8861.
28. Bush JA, Cheung KJJ, Gang L. Curcumin induces apoptosis in human melanoma cells through a Fas receptor/caspase-8 pathway independent of p53. Exp Cell Res 2001; 271: 305-314.
29. Strait KA, Warnick CT, Ford CD, Dabbas B, Hammond EH, Iistrup SJ. Histone deacetylase inhibitors induce G2-checkpoint arrest and apoptosis in cisplatinum-resistant ovarian cancer cells associated with overexpression of the Bcl-2-related protein Bad. Mol Cancer Ther 2005; 4: 603-611.
30. Watson JL, Greenshields Hill R, Hilchie A, Lee PW, Giacomantonio CA, Hoskin DW. Curcumin-induced apoptosis in ovarian carcinoma cells is p53-independent and involves p38 mitogen-activated protein kinase activation and downregulation of Bcl-2 and surviving expression and Akt signaling. Cancer Lett 2010; 297: 1-8.
31. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of human bax gene. Cell 1995; 80: 293-299.
32. Domingo-Domenech J, Pippa R, Tapia M, Gascon TM, Bachs O, Bosch M. Inactivation of NF-kappaB by proteasome inhibition contributes to increased apoptosis induced by histone deacerylase inhibitors in human breast cancer cells. Breast Cancer Res Treat 2008; 112: 53-62.
33. Chen YR, Tan TH. The cJun N-terminal kinase pathway and apoptosis signaling. Int J Oncol 2000; 16: 651-662.